Supernus Pharmaceuticals, Inc. provided earnings guidance for the year 2024. For the year, the company expects total revenues (includes approximately $125 - $135 million of Trokendi XR and Oxtellar XR) of $580 million - $620 million, and Operating loss of $30 million - $0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.96 USD | -3.47% | -6.07% | +0.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.07% | 1.59B | |
+7.91% | 72.81B | |
+12.64% | 9.13B | |
-10.56% | 5.13B | |
+58.79% | 4.99B | |
+4.07% | 3.9B | |
-16.90% | 2.48B | |
-26.13% | 2.32B | |
+19.31% | 2.17B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024